FDA’s Goodman Is Rising Star Within Agency As Obama Team Coalesces
FDA's top biologics review manager Jesse Goodman is taking on a more prominent role within the agency and HHS as FDA realigns its management in anticipation of the arrival of Commissioner-designate Margaret Hamburg and her principal deputy Joshua Sharfstein
You may also be interested in...
Senior career FDA officials are viewing the selection of FDA Commissioner-nominee Margaret Hamburg with open minds. From the perspective of the core of FDA's drug regulatory activities, the staff view Hamburg's relative lack of experience as creating a clean slate
Former New York City Health Commissioner Margaret Hamburg is preparing for her confirmation hearings as FDA commissioner, with the White House set to announce her nomination shortly
Janet Woodcock's move to become director of the Center for Drug Evaluation and Research illustrates the operational challenges FDA faces: The agency remains deeply committed to its historic bargain with the drug industry to take user fees in order to improve application review, but it is finding it increasingly hard to meet deadlines or to perform any other outside projects